中信建投证券股份有限公司 2024 年度股东大会 会议资料 2025 年 6 月 会议议程 现场会议开始时间：2025 年 6 月 27 日（星期五）14:30 现场会议召开地点：北京市朝阳区景辉街 16 号院 1 号楼泰康集团大 厦 13 层会议室 网络投票：采用上海证券交易所网络投票系统，通过交易系统投票平 台的投票时间为股东大会召开当日的交易时间段，即 9:15-9:25、 9:30-11:30、13:00-15:00；通过互联网投票平台的投票时间为股东大会 召开当日的 9:15-15:00。 召集人：中信建投证券股份有限公司董事会 现场会议基本程序： 一、宣布会议开始 二、宣布会议出席情况，推选计票人和监票人 三、审议议案 四、现场投票 五、休会，汇总现场及网络投票结果（最终投票结果以公告为准） 目 录 | 议案一：关于《中信建投证券股份有限公司 | 2024 年度董事会工作报告》的议案1 | | | --- | --- | --- | | 议案二：关于《中信建投证券股份有限公司 | 年度监事会工作报告》的议案6 2024 | | | 议案三：关于 2024 | 年度财务决算方案的议案 | 12 | ...

Core Viewpoint - CITIC Construction Investment (601066) predicts a 5% growth in electrolytic aluminum demand for 2024, demonstrating strong momentum to overcome the decline in consumption from the real estate sector, thereby reversing market expectations with solid fundamentals [1] Industry Summary - The market is currently cautious due to concerns over export competition and preemptive aluminum consumption driven by photovoltaic installations [1] - Despite negative growth in photovoltaics and weakening exports, the global electrolytic aluminum market remains balanced throughout the year [1] - The aluminum price has the capacity to withstand weak consumption cycles due to low inventory levels and weak supply elasticity, while showing significant elasticity during strong consumption cycles [1] - The industry is recommended to embrace the electrolytic aluminum sector, characterized by weak supply and high profit potential [1]

智通财经5月28日电，利弗莫尔证券显示，上海凯诘电子商务股份有限公司向港交所提交上市申请书， 独家保荐人为中信建投国际。 ...

Core Viewpoint - The company, Heilongjiang Tianyouwei Electronics Co., Ltd., is utilizing raised funds to replace pre-invested self-raised funds for its projects and to cover issuance costs, following regulatory compliance and internal approvals [2][5][7]. Fundraising Overview - The company has been approved to publicly issue 40 million shares at a price of 93.50 RMB per share, raising a total of 3.74 billion RMB, with a net amount of approximately 3.53 billion RMB after deducting issuance costs of about 213.06 million RMB [2][3]. - The total amount of over-raised funds is approximately 522.58 million RMB, and all raised funds have been deposited [2][3]. Fund Utilization - The raised funds will be allocated to several projects, including: - Automotive Electronics Intelligent Factory Construction - Intelligent Cockpit Production Base Construction - Harbin Global Automotive Electronics R&D Center Construction - Korean Automotive Electronics Factory Construction - The total planned investment for these projects is approximately 3.68 billion RMB, with adjustments leading to a new total of about 3.53 billion RMB [3][4]. Pre-Investment of Self-Raised Funds - As of May 9, 2025, the company has pre-invested approximately 285.05 million RMB of self-raised funds into the projects, which it plans to replace with the raised funds [4][6]. - The company has also pre-paid issuance costs totaling approximately 21.31 million RMB, with about 891.51 thousand RMB to be replaced by the raised funds [4][6]. Approval Process - The board of directors and the supervisory board approved the use of raised funds to replace pre-invested self-raised funds and issuance costs on May 28, 2025, confirming compliance with relevant regulations [5][6][7]. - The approval process adhered to the requirements set forth by the Shanghai Stock Exchange and other regulatory guidelines, ensuring no conflict with the implementation of the fundraising projects [6][7].

中信建投证券股份有限公司 关于浙江海正生物材料股份有限公司 差异化分红事项的核查意见 中信建投证券股份有限公司（以下简称"保荐机构"、"中信建投证券"）作为 浙江海正生物材料股份有限公司（以下简称"公司"或"海正生材"）首次公开发行 股票并在科创板上市及进行持续督导的保荐机构，根据《上海证券交易所科创板 股票上市规则》《证券发行上市保荐业务管理办法》《上海证券交易所上市公司 自律监管指引第7号——回购股份》等有关法律法规和规范性文件的要求，对海 正生材2024年度利润分配涉及的差异化分红事项进行了核查，并发表核查意见如 下： 一、本次实施差异化权益分派的原因 集中竞价交易方式回购公司股份方案的议案》，同意公司使用自有资金通过集中 竞价交易方式回购公司股份。回购股份用于公司股权激励或员工持股计划，回购 价格不超过人民币12.00元/股（含），回购资金总额不低于人民币2,000万元（含）， 不超过人民币3,000万元（含），具体回购股份的数量以回购期满时实际回购的 股份数量为准。回购期限自董事会审议通过本次回购方案之日起12个月内。 根据《上海证券交易所上市公司自律监管指引第7号——回购股份》第二十 二条规定"上 ...

中信建投证券股份有限公司 关于袁隆平农业高科技股份有限公司 使用募集资金置换已支付发行费用的自筹资金的 中信建投证券股份有限公司（以下简称"中信建投证券" "保荐人"）作为袁 隆平农业高科技股份有限公司（以下简称"隆平高科" "公司"）向特定对象发行 股票的保荐人，根据《证券发行上市保荐业务管理办法》《上市公司监管指引第 自律监管指引第 1 号——主板上市公司规范运作》等相关法律法规的要求，对隆 平高科使用募集资金置换已支付发行费用的自筹资金的事项进行了审慎核查，具 体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会出具的《关于同意袁隆平农业高科技股份有限公 司向特定对象发行股票注册的批复》（证监许可〔2025〕700 号）核准，公司本 次向特定对象发行股票数量 152,477,763 股，发行价格 7.87 元/股，募集资金总额 为人民币 1,199,999,994.81 元，扣除发行费用（不含税）人民币 12,473,584.90 元， 募集资金净额为人民币 1,187,526,409.91 元，募集资金已于 2025 年 4 月 18 日划 至公司指定账户。天健会计师事务所（特殊普通合伙）对公 ...

Core Viewpoint - CITIC Securities initiated coverage on Fosun International (00656.HK) with a "Buy" rating, highlighting the company's diversified asset portfolio and robust growth in asset quality, which warrants market attention [1]. Health Sector - Fosun's health sector encompasses pharmaceuticals, medical devices, diagnostics, and healthcare services, with key products including Hanlikang, Hanquyou, Hanshuang, and Yikaida [2]. - Hanlikang is the first domestically produced rituximab approved for treating lymphoma, leukemia, and rheumatoid arthritis; Hanquyou is a trastuzumab approved in over 50 countries for HER2-positive breast and gastric cancer; Hanshuang is the first PD-1 monoclonal antibody approved for first-line treatment of small cell lung cancer in over 30 countries; Yikaida is the first CAR-T product in China for relapsed/refractory large B-cell lymphoma [2]. Leisure Sector - The leisure sector is being optimized with a focus on brand development, particularly through the Oriental aesthetics concept, with Yuyuan Holdings enhancing its financial stability and multi-brand strategy [2]. - Club Med, under Fosun Tourism, achieved record revenue by focusing on high-end all-inclusive offerings, while Atlantis Sanya reached new occupancy highs, maintaining brand competitiveness [2]. Wealth Sector - The asset quality of Fosun's wealth sector is steadily improving, with Fosun Portugal Insurance projected to achieve approximately €6.17 billion in gross premium income in 2024, increasing the international business share from about 5% in 2014 to 29.8% [3]. - Domestic insurance companies, including Fosun P&C and Fosun United Health Insurance, are experiencing significant growth, with Fosun P&C's total premium income expected to rise from RMB 4.35 billion in 2023 to RMB 9.25 billion in 2024, both companies achieving profitability [3]. - The ongoing growth of these companies is expected to lay a solid foundation for the group's future development [3].

上市首日，三元生物创下上市以来最高价报146.00元。该股目前处于破发状态。 三元生物首次公开发行股票募集资金总额为36.86亿元，扣除发行费用后募集资金净额为35.47亿元。该 公司最终募集资金净额比原计划多26.47亿元。三元生物于2022年1月28日披露的招股说明书显示，该公 司拟募集资金9.00亿元，分别用于年产50000吨赤藓糖醇及技术中心项目、研发信息中心建设项目、补 充流动资金。 中国经济网北京5月28日讯三元生物（301206）(301206.SZ)今日股价下跌，截至收盘报29.60元，跌幅 3.58%。 三元生物于2022年2月10日在深交所创业板上市，公开发行3372.10万股，发行价格为109.30元/股，保荐 机构(主承销商)为中信建投（601066）证券股份有限公司，保荐代表人为陆丹君、陈磊。 2022年6月10日，三元生物披露了2021年年度权益分派实施公告。公司2021年年度权益分派方案为：以 公司现有总股本1.35亿股为基数，向全体股东每10股派10元现金(含税)，同时，以资本公积金向全体股 东每10股转增5股。分红前公司总股本为1.35亿股，分红后总股本增至2.02亿股。本次 ...

Core Insights - The main contract of the CSI 1000 Index futures closed at 2506 on May 28, with a slight decrease of 0.32% and a trading volume of 120,200 contracts [1][2] - Total trading volume for all contracts was 164,900, down by 30,100 contracts from the previous day [1][4] - The top 20 positions showed a net short position with a difference of 11,342 contracts [1] Group 1: Trading Volume and Positions - The total trading volume for the main contract was 120,200 contracts, reflecting a decrease of 30,100 contracts from the previous day [1] - The top 20 long positions totaled 223,800 contracts, down by 9,343 contracts, while the top 20 short positions totaled 250,400 contracts, down by 9,988 contracts [1][4] - The top three long positions were held by Guotai Junan (44,355 contracts), CITIC Futures (41,694 contracts), and Guotou Futures (13,197 contracts) [1][4] Group 2: Changes in Long and Short Positions - The top three long position increases were from GF Futures (5,056 contracts, up by 113), Shenyin Wanguo (2,850 contracts, up by 18), and Guoxin Futures (3,845 contracts, up by 15) [1] - The top three long position decreases were from CITIC Futures (23,985 contracts, down by 2,857), Guotai Junan (24,231 contracts, down by 1,415), and Dongzheng Futures (8,295 contracts, down by 1,325) [1] - The top three short position increases were from Huatai Futures (7,699 contracts, up by 163), Shenyin Wanguo (3,831 contracts, up by 84), and Zhongjin Futures (2,299 contracts, up by 80) [1]

中信建投团队认为，中东优质银行在信贷增速、息差水平及非息收入动能上均显著超越同业，长期ROE有望超越15%，部分头部机构或突破20%，形成超额 收益空间。 【环球网财经综合报道】中信建投近期的一份研究报告剖析中东地区作为全球经济高增长极的独特潜力，揭示区域银行业兼具高成长、高回报与高稳健性的 多重优势。报告分析认为，中东银行凭借区域经济红利及差异化竞争优势，或成为全球投资者不可忽视的价值洼地。 报告显示，中东地区凭借政治智慧、经济改革及现代化转型战略，正成为全球发展最快的区域之一。阿联酋、沙特阿拉伯、卡塔尔等核心国家加速推 进"2030"经济转型计划，非石油产业GDP占比提升至70%，经济增长模式多元化成效显著。迪拜、阿布扎比及沙特阿拉伯凭借开放政策及战略区位优势，成 为经济活力与创新动能的集聚地，为银行业务扩展提供广阔空间。 中信建投分析指出，中东银行业呈现四大核心特征：高ROE与高股息；汇率风险可控；信贷与盈利双优；资产质量改善。 报告聚焦阿联酋和沙特两大核心市场，提炼三大维度：区域优选：阿布扎比、迪拜因开放政策及经济多元化程度高，具备更强的区域协同效应；沙特阿拉伯 市场潜力巨大，成长机遇显著。银行禀赋： ...